Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Therapeutic Focus
  5. Endocrine

Endocrine

Evaluate

Thumbnail
June 05, 2023

Akero suggests the limits of GLP-1s in Nash

Thumbnail
June 01, 2023

US FDA approval and panel tracker: May 2023

Article image
Vantage logo
June 01, 2023

Novo seeks a cardiovascular boost

An outcomes trial could increase demand for Wegovy even further – if pricing, and production, can be worked out.

Article image
Vantage logo
May 25, 2023

Lilly steps up its oral obesity push  

Article image
Vantage logo
May 23, 2023

Novo Nordisk looks towards a skinny pill

Article image
Vantage logo
May 22, 2023

Intercept’s Nash exit feels inevitable

Article image
Vantage logo
May 22, 2023

Clearance makes Beta Bionics look like a target

Article image
Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

A hit on one goal helps, but future Nash data will be more decisive.

Article image
Vantage logo
May 10, 2023

Boehringer and Zealand take a baby step in obesity

Article image
Vantage logo
May 04, 2023

Novo’s Wegovy launch stalls again

Article image
Vantage logo
April 24, 2023

Medtronic plays catch-up in diabetes

The long-awaited US approval of its newest artificial pancreas comes through, but Medtronic remains behind.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up